Work is supported by the CD4 Initiative at Imperial College London.

The Imperial College London selected Zyomyx to work on a new treatment management tool for HIV/AIDS patients in developing countries. The company will codevelop a test to count CD4+ T-lymphocytes in blood.

Zyomyx will receive milestone-dependent payments from Imperial College over the next four years for the development of this technology. Upon successful completion of the development program, the company intends to manufacture the resulting product for global release.

“The absence of inexpensive, rapid, and robust CD4-counting tools jeopardizes global initiatives for fighting AIDS,” remarks Peter Wagner, Ph.D., president and CEO of the company. “The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development and launch of an advanced but simple and inexpensive CD4 cell counting product that will meet the demanding specifications for use in developing countries.”

Imperial College’s CD4 Initiative is funded by the Bill & Melinda Gates Foundation.

Previous articleBioAlliance Pharma Establishes European Joint Venture with Spepharm
Next articleAvax and Cancer Treatment Centers of America to Work on Personalized Vaccine for Ovarian Cancer